

1 **Home Care Follow up determine the point of inversion of IL-6 levels in**
2 **relation to C-Reactive Protein as the cytokine storm marker in COVID-19**

3

4 Running title

5

6 **Success of the early and longitudinal markers-based monitoring in**
7 **COVID-19**

8

9 Sérgio Paulo de Mello Mendes Filho¹, Fernanda Simão Martins¹, Paulo Jose Giroldi²,
10 Raul Honorato e Melo¹, Edcleia Lopes de Oliveira², Anibal Borin dos Santos¹, Dayse
11 Cristina Oliveira Medeiros¹, Sergio de Almeida Basano³, Jéssica Amaral Lopes⁴, Yury
12 Oliveira Chaves^{5,6}, Rebeca Sousa Pinheiro^{5,6}, Luís Marcelo Aranha Camargo⁷, Juliana
13 Pavan Zuliani⁴, Paulo Afonso Nogueira^{5,6*},

14

15 1. Serviço de Assistência Médica Domiciliar (SAMD); Secretaria Estadual da Saúde
16 (SESAU), Av. Gov. Jorge Teixeira, 3734, Industrial, 76821-092, Porto Velho/RO,
17 Brazil;

18 2. Laboratório Estadual de Patologia e Análises Clínicas (LEPAC); Av. Gov. Jorge
19 Teixeira, Industrial, 7245-7385, Porto Velho/RO, Brazil;

20 3. Hospital Cemotron; Av. Guaporé, 215, Lagoa, 78918-791, Porto Velho/RO, Brazil;

21 4. Fundação Oswaldo Cruz – Rondonia (FIOCRUZ – RONDONIA); Rua da Beira, 7671,
22 Lagoa, 76812-245, Porto Velho/RO, Brazil;

23 5. Instituto Leônidas e Maria Deane (ILMD), Fundação Oswaldo Cruz – Amazonas
24 (FIOCRUZ – AMAZONAS); Rua Terezina, 476, Adrianópolis, 69057-070; Manaus/AM,

25 Brazil

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Pedro de Teixeira Ave, Dom
27 Pedro, 69040-000, Manaus/AM, Brazil

28 7. Instituto de Ciências Biomédicas V (ICB5), Universidade de São Paulo (USP) -
29 Campus Monte Negro; Avenida Francisco Prestes Maia, 2728, Setor 2, 76888-000, Monte
30 Negro/RO, Brazil;

31

32 *Corresponding author:

33 Paulo Afonso Nogueira, paulo.nogueira@fiocruz.br, cell phone 5592994851620

34 Instituto Leônidas e Maria Deane (ILMD), Fundação Oswaldo Cruz – Amazonas
35 (FIOCRUZ – AMAZONAS); Rua Terezina, 476 - Adrianópolis, 69057-070; Manaus/AM,
36 Brazil.

37

38 **Funding:**

39 Rondônia State Health Department Budget.

40

41

42

Abstract

43

44 The IL-6 has been used for the characterization of the cytokine storm induced by
45 SARS-CoV-2, but so far, no one has found out when and in whom the cytokine
46 storm develops. Our study demonstrates how early and longitudinal clinical-
47 based monitoring and dosing of five markers (C-reactive protein, IL-6, fibrinogen,
48 ferritin and D-dimer) helped to identify who'd developed the cytokine storm. The
49 peak of IL-6 in pg/mL proportionally higher than the peak of CRP in mg/L was
50 sufficient to define the timing of the evolution of cytokine storm syndrome. The
51 administration of antibiotic therapy, anticoagulant therapy and pulse therapy
52 resolved the infection and prevented the progressive deterioration of the lung
53 function of the patients with potential for development of severe COVID-19.

54

55 Introduction

56 The evolution to severe acute respiratory syndrome (SARS) in patients
57 with severe COVID-19 is triggered by a remarkable and uncontrolled lung
58 inflammation characterized by a systemic increase in cytokines and chemokines,
59 known as the macrophage activation syndrome (MAS) or more usually called a
60 "cytokine storm" [1–5]. MAS can directly induce tissue damage, coagulopathy,
61 dyspnea, hypoxemia, hypotension and hemostatic imbalance, which induces a
62 necessity of mechanical ventilation and increases the risk of death [2,3,6–10].

63 A virus-induced cytokine storm includes fever, coagulopathy and immune
64 cell-mediated responses, sharp elevations in acute phase responses

65 [characterized by increases in interleukin 6 (IL-6), ferritin, and C-reactive protein
66 (CRP)] [9,11–17].

67 Several studies have addressed that in some cases COVID-19 patients
68 developed MAS similarly to the *hemophagocytic lymphohistiocytosis* (HLH)
69 syndrome [13,18–20]. The HLH is characterized by an exacerbation of innate
70 responses with increases in the CRP levels, ferritin, fibrinogen, D-dimer and
71 interleukin-1 (IL-1) and IL-6 [21]. It is immediately treated via pulse therapy with
72 corticosteroids, anticoagulants, broad-spectrum antibiotics in order to prevent
73 superinfections, and inhibitors of interleukins and immunoglobulins [19,21,22].

74 Regarding SARS-CoV-2, IL-6 has been used for the characterization of
75 the cytokine storm in severe COVID-19; however, hypoxemia has been the
76 criterion that helps to determine the administration of corticosteroids. Historically,
77 corticosteroids have been effective in immunomodulating hyperinflammation in
78 patients with severe acute respiratory syndrome coronavirus (SARS-CoV) and
79 Middle East respiratory syndrome coronavirus (MERS-CoV). However, the use
80 of corticosteroids, both in COVID-19 and in the SARS and MERS epidemics, has
81 become a great conundrum, since the early use led to adverse consequences
82 such increased viral load and worsening of the disease, but when properly
83 administered, corticosteroids lead to an amelioration, such as reduction of fever,
84 improvement of oxygenation and reduction of mortality rate [2,23,24]. Even so,
85 the appropriate timing and dosage for their administration still represent a
86 dilemma in which there is a choice between uncontrolled viral infection versus
87 reduced progressive deterioration of oxygenation indicators, rapid imaging
88 progress and excessive inflammatory response [23,25].

89 Thrombotic complications are also an important issue in COVID-19 [26–
90 33]. Clinical and laboratory findings of COVID-19 patients included
91 thrombocytopenia, elevated D-dimer, prolonged prothrombin time, and
92 disseminated intravascular coagulation [33,34]. In addition, elevated D-dimer
93 levels and hyperfibrinogenemia were used as criteria for the application of an
94 aggressive thromboprophylaxis [31]. Still, co-infections involving respiratory
95 bacteria and viruses are commonly identified as important causes of morbidity
96 and mortality [35,36]. In COVID-19, secondary bacterial infections are more
97 common than co-infections, especially in patients developing severe COVID-19
98 [37]. CRP is often used as a solution for a clinical dilemma. Although it is an acute
99 phase protein in response to inflammation, it is the only point-of-care biomarker
100 of bacterial infection used to determine antibiotic treatment in patients with acute
101 respiratory infections as well as for monitoring antibiotic treatment in patients with
102 known bacterial infections and for differentiating between bacterial and viral
103 infections in various clinical situations [38–41].

104 In the present study, we will demonstrate how the early and longitudinal
105 monitoring clinical-based practice, as well as quantifying 5 markers (CRP, IL-6,
106 fibrinogen, ferritin, D-dimer) daily has served to reduce the rates of mortality due
107 to COVID-19 among the health professionals from Porto Velho, the capital of the
108 Rondônia state. This longitudinal follow-up of inflammatory markers subclassified
109 patients among those who needed only antibiotic therapy (defined here as
110 YELLOW PATIENT); those in which antibiotic therapy and anticoagulant therapy
111 were sufficient for resolution of COVID-19 (RED PATIENT); and the third group
112 in which COVID-19 evolved into a severe disease (PURPLE PATIENT), and for
113 which antibiotic therapy, anticoagulant therapy and pulse therapy administration

114 resolved the infection and prevented the progressive deterioration of lung injury.
115 To this end the observation of CRP and IL-6 kinetics levels can be markers to
116 distinguish the timing of the cytokine storm in patients with a more severe form of
117 COVID-19 in relation that one that presented COVID-19 with endothelial injury
118 determining the therapy to be conduct.

119

120 **Materials and Methods**

121 **COVID-19 severity early identification plan**

122 The state of Rondônia instituted the Home Medical Care Service (HMCS)
123 more than 10 years ago to treat patients with chronic diseases via home care, to
124 relieve overcrowding the public hospitals in the state network. With the
125 emergence of the SARS-CoV-2 pandemic, this service was intensified in view of
126 the high mortality rates of health professionals due to fight against COVID-19.
127 The principal goal was the early identification of cases followed by a severity
128 analysis and follow-up based on daily monitoring of clinical-laboratory parameters
129 to assess the patient's vulnerability potential. This follow-up was carried out by
130 the HMCS and consisted of a nursing team responsible for blood sample
131 collection, monitoring of vital signs and medicine administration when necessary,
132 and a medical remote health team that, when necessary, included a physical visit.
133 The Rondonia State Laboratory of Pathology and Clinical Analysis (LEPAC)
134 supplied the kits for measure the markers used for the follow-up of the patients.
135 The State Coordinating Office for Management and Pharmaceutical Assistance
136 carried out the provision of supplies and medicines to avoid shortages and enable

137 an uninterrupted flow of administration to the patients. Laboratory tests were
138 performed daily by LEPAC.

139

140 **Clinical and laboratory monitoring of patients with COVID19**

141 Health professionals as well as military personnel and their respective
142 family members were referred to the Oswaldo Cruz Polyclinic (OCP) where they
143 were submitted to a medical evaluation and diagnoses of SARS-CoV-2 infection
144 by RT-PCR, via intranasal swab sample collection, or rapid serological test. There
145 was a total of 8,902 visits to the Oswaldo Cruz Polyclinic (OCP) in the period from
146 2nd June 2020 to 31st December 2020. Of this, 631 patients were followed up by
147 HMCS due to clinical laboratory markers alterations. Within this group of patients,
148 we had four deaths. Mortality of patients cared for by the HMCS was 0.045%.

149 The methodology used for the running of HMCS follows: the medical
150 evaluation screened the patients for vital signs and the severity of infection. All
151 patients who had no advanced symptoms or signs of clinical deterioration were
152 referred for laboratory markers quantifying at LEPAC. Depending on the results
153 of this laboratory markers and the clinical condition, daily follow-up was
154 conducted involved laboratory markers new determinations' when necessary.
155 The treatment was also personalized at home by a HMCS nursing team followed
156 by checking vital signs and administering medication. The medical team carried
157 out the remote monitoring and, when necessary, carried out a physical visit.

158 The study was approved by the Fundação de Medicina Tropical Dr. Heitor
159 Vieira Dourado Ethics Review Board (CAAE: 51963021.9.0000.000) and the
160 requirement for informed consent was waived by the Ethics Commission because

161 these data come from medical and laboratory assistance that took place between
162 2020 and 2021 and medical records were available anonymously encoded.

163

164 **Screening of patients**

165 During the medical consultation, patients who presented signs of clinical
166 severity evidenced by a Glasgow score of ≤ 14 , respiratory rate above 24
167 respiratory incursions per minute (RIPM) and O₂ saturation less than 90% were
168 referred for hospitalization to receive therapeutic and ventilatory support or
169 admission to the ICU. If the patient had a respiratory rate between 21 and 24
170 RIPM or alterations in any of the laboratory markers such as CRP, fibrinogen, D-
171 dimer, ferritin and IL-6, the patient was immediately followed up at home on a
172 personalized and daily basis by the HMCS.

173

174 **Study population and risk classification**

175 All patients were grouped according to the clinical signs and symptoms
176 and laboratory markers in BLUE, GREEN, YELLOW, RED or PURPLE patient as
177 follows:

178 - BLUE PATIENT: Patients that do not present alterations in laboratory markers
179 and were classified as having a viral syndrome. All these patients were instructed
180 to take 10,000 U vitamin D every 48 h due to hypovitaminosis of vitamin D being
181 described in patients with severe COVID-19 [42]. In addition, 600 mg of
182 acetylcysteine every 12 h were prescribed due to its glutathione-forming
183 potential, which protects against oxidation by iNOS [43].

184 - GREEN PATIENT: characterized as patients that only presented increased
185 ferritin levels. For these patients, a therapeutic based on iron metabolism to
186 decrease the uptake and absorption of iron [44] was prescribed, as well as
187 vitamin D and acetylcysteine as mentioned above. The therapy was composed
188 of i) 60 mg of chelated zinc as an inhibitor that competes with serum iron ion; ii)
189 proton pump inhibitor 2 h before lunch to control gastric acidity to prevent the
190 transformation of ferric ions into ferrous ions absorbed in the intestine; iii)
191 restriction of red meat intake because it is the main source of iron.

192 - YELLOW PATIENT: Patients showed elevated CRP in the first examinations,
193 without increases in fibrinogen. These patients required only antibiotic therapy
194 and CRP levels served as a guide [41]. If an increase in CRP greater than 5 and
195 less than 20 mg/L, more than 24 RIPM and/or fever, antibiotic therapy with
196 amoxicillin clavulanate for 7 days was provided. CRP greater than 20 mg/L were
197 given venous antibiotic therapy with amoxicillin clavulanate with levofloxacin or
198 oral doxycycline.

199 - RED PATIENT: Include the ones who presented significant increases in CRP
200 and IL-6 concomitantly, and principally due to alterations in fibrinogen. These
201 patients received antibiotic therapy with amoxicillin clavulanate and 1 mg/kg/day
202 of enoxaparin. They were characterized as having a severe endothelial lesion
203 due to increased fibrinogen even after 1 mg/kg/day of enoxaparin for more than
204 48 h.

205 - PURPLE PATIENT: Initially all were classified as RED PATIENTS but evolved
206 to cytokine storm syndrome. Some of them responded with alterations in CRP,
207 ferritin, and IL-6, in addition to fibrinogen. Even when after returning to normal
208 levels, these patients presented proportionally higher IL-6 levels than CRP levels,

209 which indicated an exacerbation of cytokines, and fibrinogen rose again after a
210 few days. For these patients, in addition to antibiotic coverage, the treatment
211 conducted with 2 mg/kg/day of enoxaparin, deworming with ivermectin to avoid
212 the risk of strongyloidiasis infestation, and pulse therapy with 20 mg
213 dexamethasone on the 1st day followed by 3 days of 10 mg/day and 3 days of 5
214 mg/day.

215

216 **Results**

217 **Subclassification of patients based on follow-up of the five laboratory** 218 **markers**

219 Six hundred thirty-one patients had clinical laboratory alterations and were
220 grouped according to the clinical and laboratory symptoms described above. To
221 demonstrate biochemical and hematological parameters in the first examination
222 a sampling of the total patients was used ([Table 1](#)) such as twenty-seven of BLUE
223 PATIENT group; twenty-eight of YELLOW PATIENT group; twenty-three of RED
224 PATIENT group and thirty-two of PURPLE PATIENT group. In addition, a group
225 of 27 cases, between 30 and 55 years-old, with a RT-PCR negative diagnosis of
226 COVID-19 and no symptoms was recruited to be followed up as a CONTROL
227 group. The analysis did not show differences between patients belong to either
228 YELLOW, RED or PURPLE groups, little changes in the neutrophil/lymphocyte
229 ratio and in TGO and TGP levels were observed in PURPLE group. To this end,
230 this first examination follow-up cases with the five laboratory markers was
231 important for the subclassified patients.

232 The YELLOW PATIENT group showed CRP elevations, and the use of
233 antibiotics decreased continuously these levels until the baseline (Figure 1A). In
234 these patients, IL-6 levels behaved more timidly and decreased synchronously
235 with CRP levels (Figure 1B). Fibrinogen levels did not exceed the limit of 437
236 mg/dL despite the mild increase in IL-6 levels (Figure 1C) and, therefore, the use
237 of enoxaparin was not necessary. Without increased in fibrinogen levels, there
238 was no thrombus formation and, therefore, the D-dimer, a predictor of fibrinolysis,
239 did not increase (Figure 1D). Figure 1E shows the ferritin curve in women. The
240 variation showed that some female patients demonstrated iron metabolism
241 disorder, requiring treatment according to the initial protocol. Antibiotic treatment
242 led to decreased CRP and IL-6 levels. Figure 1F demonstrated the ferritin levels
243 in men. In most of the male patients, ferritin levels were much higher than in
244 women in the first examination, which is probably due to the eating habits of men.
245 Similarly, the treatment of iron metabolism and control of metabolic syndromes
246 resulted in optimal results, with the decrease of ferritin levels and the reduction
247 of CRP and IL-6 levels concomitantly. These patients had mild to moderate
248 clinical symptoms, anosmia, cough, fever, and chest discomfort, and they did not
249 require the oxygen support.

250 Figure 2 represents the behavior of the markers in RED PATIENTs who
251 received venous antibiotic therapy and subcutaneous anticoagulant and evolved
252 to improvements in clinical signs and laboratory results. These patients were
253 treated with 1 mg/kg/day of enoxaparin which resulted in reversal of fibrinogen
254 levels to normal titers. CRP started with higher levels and, when patients were
255 treated with venous antibiotic therapy, they had progressive resolution (Figure
256 2A). The increase in IL-6 levels accompanied the increases in CRP, but when

257 CRP levels were below 25 mg/L, with the venous antibiotic therapy there was a
258 gradual decrease in IL-6 to normal levels (Figure 2B). In Figure 2C it is possible
259 to observe how increased fibrinogen was used within this protocol as the standard
260 for anticoagulant use (see red arrow). The graph demonstrated that after the
261 increase of fibrinogen levels above 437 mg/dL, the indication of a daily dose of 1
262 mg/kg/day of enoxaparin for nine days was sufficient for the normalization of the
263 results. In Figure 2D it is presented the increase in D-dimer levels on the second
264 day of examination demonstrating that these patients had already had previous
265 increases in fibrinogen, since the peak that occurred on the fifth day of
266 examinations represented the increase in fibrinogen on the second day (Figure
267 2C). After this, the D-dimer curve showed that the patient no longer had
268 fibrinolytic activity after anticoagulant therapy. In this group, female patients
269 already showed higher levels of ferritin (Figure 2E). Regarding the male patients,
270 most of them also had alterations associated with metabolic syndromes (Figure
271 2F).

272 Figure 3 describes the behavior of the markers of patients who underwent
273 an abrupt increase in IL-6 levels, which is the main marker for the characterization
274 of a cytokine storm. In Figure 3A, CRP levels in these patients began with high
275 levels and, after the start of antibiotic therapy, there is a progressive drop.
276 Between sixth-eighth day of illness, in patients with the most severe symptoms,
277 IL-6 levels increased earlier than those of CRP levels, and the peak of IL-6 in
278 pg/mL is proportionally higher than the peak of CRP in mg/L (see thick green
279 arrow, Figure 3B). This abrupt increase characterizes the cytokine storm, which
280 was treated with high-dose corticosteroids and resulted in a significant drop in the
281 release of IL-6 until they reach normal levels. This drop is also observed with

282 CRP levels. In [Figure 3C](#), in the graph showing the fibrinogen levels it is clearly
283 demonstrated that when the patient was recruited by the service, the patient
284 already presented increased levels of CRP, IL-6 and fibrinogen levels (see thin
285 red arrow), which demonstrates that these patients had already had the disease
286 for several days. The introduction of antibiotic therapy with enoxaparin at 1 mg/kg
287 correlates with the drop of fibrinogen to normal levels, but the sharp increase in
288 IL-6 levels, which denotes a cytokine storm, creates a new increase in fibrinogen
289 levels that is characterized as a second wave, even when using 1 mg/kg of
290 enoxaparin. The re-appearance of an elevation in fibrinogen was an indicator for
291 an increase in anticoagulation therapy with enoxaparin of 2 mg/kg day (see blue
292 and red thick arrows, [Figures 3A](#) and [C](#)). This results in the start of the decrease
293 of these markers to normal levels. In [Figure 3D](#), the first increase in D-dimer levels
294 occurred a few days after the peak of fibrinogen levels, around the eighth to tenth
295 day. The new increase in D-dimer occurred on the thirteenth day, which was after
296 the second peak of fibrinogen levels that was observed between the eighth to the
297 tenth day ([Figure 3C](#)). In [Figure 3E](#), the increase in ferritin levels in female
298 patients shows that these patients have had the disease for some days, and from
299 the sixth day, there is an exponential increase and the patient's improvement
300 response is translated into the decrease in the curve. [Figure 3F](#) showed the
301 increase in ferritin levels in male patients, with an expected upward and
302 progressive curve as can be seen in infections, but around the sixth to seventh
303 day there is a greater than 80% increase in relation to the previous day,
304 demonstrating that ferritin is an excellent marker of inflammatory response. Only
305 patients who developed this abrupt increase compared to the previous day were
306 treated with corticosteroid via pulse therapy. The observation of CRP and IL-6

307 kinetics levels allowed us to distinguish the timing of the cytokine storm in patients
308 with a more severe form of COVID-19 in relation that one that presented COVID-
309 19 with endothelial injury. Although the units of CRP and IL-6 are different, at the
310 beginning of the disease the kinetics of CRP and IL-6 levels in these two groups
311 of patients are similar, though with the peak IL-6 in pg/mL being higher than the
312 peak of CRP in mg/L ([Figures 4A and B](#)).

313

314 **Dynamics of laboratory markers in the determination of therapy**

315 The dynamics of serological markers allowed us to determine the antibiotic
316 therapy, the anticoagulant therapy, and the administration of pulse therapy.
317 Patients defined as having bacterial co-infection had their infection resolved only
318 with antibiotics. IL-6 and CRP levels served as a guide for the choice of the
319 spectrum of the antibiotics. These patients showed CRP alterations of between
320 5.0 and 20.0 mg/L, and IL-6 up to 30 pg/mL and received antibiotic therapy (ABT)
321 of 875 mg amoxicillin and 125 mg potassium clavulanate every 12 h for 7 days
322 ([Figure 5A](#)). Fibrinogen also served as a guide for treatment; if the fibrinogen
323 levels were less than 437 mg/dL, they continued to receive antibiotic therapy.
324 Those patients who had ferritin alterations were also prescribed vitamin D,
325 acetylcysteine and received anti-iron uptake therapy. The other markers were
326 unaltered, and the infection was resolved in these patients.

327 Patients with endothelial injury showed increases in CRP levels to over 20
328 mg/L and IL-6 up to 30 pg/mL and a concomitant increase in fibrinogen to over
329 437 mg/dL ([Figure 5B](#)). For the opportunistic infection's treatment, ABT was
330 replaced by 1 g of cefepime via venous route and 500 mg clarithromycin via oral

331 route every 12 h, and patients received 1 mg/kg/day of enoxaparin subcutaneous
332 for 7 days. If ferritin levels were high, in addition to vitamin D, acetylcysteine and
333 anti-iron uptake therapy was administered. The patients we also investigated for
334 type 2 diabetes mellitus, hepatic steatosis, and drug hepatitis, in addition to renal
335 function. The infection was resolved with antibiotics and CRP levels were
336 decreased in these patients. Treatment with 1 mg/kg/day of enoxaparin
337 decreased fibrinogen in 24 h and therefore there was no increase in D-dimer.
338 Initially, it was not observed patients with increased fibrinogen without increased
339 CRP levels, and this endothelial lesion usually came from a mixed infection.
340 Increased fibrinogen production behaved as a marker of the onset of endothelial
341 injury which results from the exposure of tissue factor in the basal membrane
342 (extrinsic via the coagulation cascade with subsequent platelet adhesion).

343 Patients with cytokine storm syndrome showed increased fibrinogen even
344 after 1 mg/kg/day of enoxaparin for more than 48 h and, even when after returning
345 to normal levels, fibrinogen levels increase again after a few days (Figure 5C).
346 Unlike patients with endothelial injury, increased fibrinogen occurred
347 concomitantly with CRP, IL-6 and ferritin levels. The follow-up of ferritin was very
348 important, since the sharp increase in its values between 70 and 100% of the
349 initial levels together with IL-6 peaks caused an exacerbation of cytokines,
350 indicating macrophage activation syndrome. In addition, patients received
351 therapy to correct metabolic syndrome and iron metabolism. These patients were
352 characterized as presenting severe endothelial lesion and the parameters
353 observed guided the treatment of a possible macrophage activation syndrome or
354 even hematophagous lymphohistiocytic syndrome. After deworming with
355 nitazoxanide to avoid the risk of strongyloidiasis infestation, these patients

356 received an increase in the range of coverage of antibiotics, with the addition of
357 meropenem and amikacin, or tazobactam, and the dose of enoxaparin was
358 increased to 2 mg/kg/day, and pulse therapy was conducted with 20 mg of
359 dexamethasone on Day 1, followed by 3 days of 10 mg/day and 3 days of 5
360 mg/day (Figure 5C).

361

362 Discussion

363 There are no data on the literature demonstrating a home care follow-up
364 of markers in COVID-19 patients [23,45,46]. Our study is the first to show a
365 clinical and laboratory follow-up of patients with COVID-19 since the first
366 symptoms conduct in home care. In a sampling of the presentation of COVID-19
367 disease, we observed this heterogeneity from asymptomatic cases to patients
368 who were evolving to SARS, as observed everywhere [3,47–49]. Some patients
369 required oxygen therapy, but daily follow-up prevented worsening and the
370 mortality rate was very low. Patients who needed oxygen fell into RED and
371 PURPLE groups. Even with the increase of the markers levels after treatment,
372 only some RED PATIENTS still needed oxygen support. In PURPLE PATIENTs,
373 the computed tomography scans have already showed a high rate of lung
374 involvement (personnel communications of clinicians from HMCS) and all
375 patients needed oxygen support. Moreover, the subclassification and monitoring
376 of the markers evaluated allowed us to understand the dynamics of the
377 pathophysiology of SARS in severe COVID-19, which is usually characterized as
378 a cytokine storm [1–5]. We had patients who presented the cytokine storm
379 syndrome and, with very rare exceptions; surprisingly none of the patients

380 evolved for the necessity of mechanical ventilation or were at risk of death, as
381 commonly observed [2,3,6–10].

382 The follow-up was completely effective regardless of a first consultation,
383 or even without a tomographic image as an effective marker of severity. These
384 observations led us to create a therapeutic protocol associated with the clinical
385 picture: CRP as a guide for the introduction of antibiotics, fibrinogen as a guide
386 for the introduction of anticoagulation therapy with enoxaparin and, IL-6 as a
387 guide for the introduction of pulse therapy, which were effective for identifying the
388 cytokine storm [29]. Thus, our greatest finding was that the administration of
389 broad-spectrum antibiotic therapy and pulse therapy with dexamethasone and an
390 increased dose of anticoagulant which contributed to resolve the infection of the
391 group of patients who had a COVID-19 of greater severity and were at risk of
392 death.

393 Moreover, our study had the opportunity to follow-up all the LEPAC results
394 from the onset of symptoms and the alterations of the evaluated markers gave
395 us clues to the worsening of the disease. The follow-up led us to believe that the
396 markers have a sequence of increases such as: CRP was the first to increase in
397 patients without symptoms, and it increased with the onset of symptoms
398 accompanied by IL-6 and ferritin levels. With the use of antibiotic therapy, CRP
399 dropped substantially in the YELLOW PATIENTs with a good therapeutic
400 response, improvement in the clinical presentation and laboratory markers in 48
401 h.

402 CRP could be a marker of opsonization at the first sign of a primary
403 bacterial infection, as well as the secondary one resulting from an infectious
404 respiratory viral disease, such as COVID-19 [37,41]. This fact makes us rethink

405 the relationship of CRP with the virus, because CRP would not decrease if it was
406 only associated with inflammation, whereas the association with high CRP being
407 most commonly associated with a secondary bacterial infection by respiratory
408 viruses [38–40,50,51]. Although prescribing broad-spectrum antibiotics is
409 important for preventing these infections, the use of antibiotics should be prudent
410 during the evolution of the SARS-CoV-2 pandemic [40,50,52].

411 In RED PATIENTS, CRP and IL-6 levels were already higher even in the
412 first days of infection, though the patients still present mild symptoms; however,
413 fibrinogen increased soon after. After antibiotic and anticoagulant therapy, the
414 markers improved with resolution of disease. The increase in fibrinogen due to
415 an even greater increase in CRP and IL-6 levels led to the use of antibiotic
416 therapy and anticoagulant treatment that resolved the infection. Our findings call
417 into question the use of fibrinogen as an early marker of this thrombotic stage, as
418 seen in the H1N1 pandemic [35,36]. According to these studies, colonization of
419 the nasopharynx with pathogenic bacteria in respiratory virus infection may
420 predispose patients to a secondary bacterial infection due to impaired mucociliary
421 clearance, thus allowing secondary bacterial invasion, formation of vasculitis
422 zones, capillary thrombosis and necrosis around the areas of bronchiolar damage
423 [35,36].

424 There are no studies on the pathophysiology of endothelial injury for tissue
425 factor exposure in COVID-19. The D-dimer has been considered one of the
426 severity criteria of SARS, suggesting that disseminated intravascular coagulation
427 leads to death in patients with COVID-19 [31,53]. However, D-dimer levels
428 increased late in relation to fibrinogen, therefore, the alterations in fibrinogen
429 observed here were indicative of the dose of anticoagulant needed in the

430 treatment of COVID-19. Thus, alterations in fibrinogen observed here were
431 resounding in exposing endothelial dysfunction and were indicative of the dose
432 of anticoagulant needed in the treatment of COVID-19.

433 The PURPLE PATIENTs had behavior similar to RED PATIENT but with
434 high levels markers in the beginning. After antibiotic and anticoagulant therapy,
435 all the markers improved and started to decrease. However, between the ninth
436 and tenth day, some patients had an 80% increase in IL-6 levels from the
437 previous day that was accompanied by a sharp increase of CRP. Although the
438 magnitude of IL-6 pg/mL is different in relation to the CRP mg/L, the peak of IL-6
439 was earlier and was superior to the peak of CRP (Figure 4). Moreover, these
440 patients had a second wave in fibrinogen evaluation that demanded us to double
441 the dose of the anticoagulant and increase the length of antibiotic therapy in the
442 course of pulse therapy. Thus, our findings bring a new understanding of the
443 sequence of the initial inflammatory response, and no longer place IL-6 as the
444 main protagonist, but the inversion of IL-6 levels in relation to CRP for the role to
445 predict the cytokine storm [54–56].

446 The cytokine storm plays an important role in the process of aggravation
447 of the disease and is considered one of the main causes of SARS [1,23,56,57].
448 IL-6 has been responsible for the characterization of the cytokine storm and MAS
449 in severe COVID-19 [11,23,45,54,58]. Effective suppression of the cytokine storm
450 is an important way to prevent the deterioration of patients with severe COVID-
451 19 [59], as has occurred with other epidemics involving SARS, MERS, and severe
452 influenza. The COVID-19 therapy (RECOVERY) randomized controlled and
453 open-label clinical trial showed that use of dexamethasone for up to 10 days
454 resulted in lower mortality over 28 days [60]. The dose used was 6 mg once a

455 day for up to 10 days or until hospital discharge, which is the standard and usual
456 care. The effectiveness of the therapy was low and its benefit was apparently
457 only a mere statistical effect [60], while the use of colchicine in adults hospitalized
458 with COVID-19 was worse [61], due likely severe COVID-19 patients were not
459 separated between who developed endothelial injury like RED PATIENTS from
460 those that developed cytokine storm characterized as PURPLE PATIENTs by the
461 peak of IL-6 followed by CRP. In these patients, their laboratory markers began
462 to demonstrate worsening as a result of the MAS [23,58,62], or even a HLH
463 syndrome [13,18,21,63], prior to the clinical picture, which sometimes did not
464 manifest itself. Our findings are in agreement with Zuñiga and Moreno-Moral
465 teams about high-dose corticosteroid pulse therapy in the increasing of the
466 survival rate of the COVID-19 patients at risk of hyper-inflammatory response
467 [64]. In addition, the pulse therapy would not be sufficient without broad-spectrum
468 antibiotic therapy and the increased dose of cutaneous anticoagulant as reported
469 in several studies [19,21–23,55,58,63].

470 Ferritin showed a peculiar behavior and was shown to be altered in some
471 patients early in the first exams. Ferritin serves to carry and store iron for vital
472 cellular processes, while protecting against toxicity of this metal for the production
473 of oxygen free radicals [22]. The follow-up of ferritin was very important because
474 a therapy to decrease the uptake and absorption of iron were given to the COVID-
475 19 patients with increased ferritin early on. These patients were clinically well
476 despite having altered ferritin levels due to a pre-existing metabolic syndromes
477 [65,66]. However, this treatment had to be stopped in order not to mask the daily
478 elevation and the increase close to the peak of IL-6 and CRP, as observed in
479 COVID-19 and in syndromes with hyperferritinemia [17,22,55,65,66]. The direct

480 role of ferritin in macrophage activation syndromes, such as COVID-19, lies in
481 the activation of macrophages that play a key role in the perpetuation of
482 hyperferritinemia [17,22,55,65,66]. Herein, patients who had a cytokine storm
483 had an increase of 80 to 100% of ferritin related to the value of the previous day.
484 This fact makes us appreciate the importance of ferritin as an optimal marker of
485 a cytokine storm, especially in those with an initial increase due to metabolic
486 syndrome, and that without prior treatment against absorption/uptake, this would
487 interfere with its reliability.

488 Our study also has some significant limitations. The drawbacks of the work were
489 that, for some patients there are not all data of five markers daily, despite our
490 efforts to perform the monitoring and dosing of five markers every day. That is
491 due some patients did not present in the LEPAC or they were not found in their
492 residences.

493 **Conclusions**

494 The home care follow-up was completely effective regardless of a first
495 consultation, or even without a tomographic image, as effective markers of
496 severity. The daily evaluation of the markers was important in order to classify
497 the severity at the onset of symptoms or even when the infection was
498 asymptomatic. CRP as a guide for the introduction of antibiotics, fibrinogen as a
499 guide for the introduction of anticoagulation therapy with enoxaparin and IL-6 as
500 a guide marker for the introduction of pulse therapy. Another observation of the
501 study was the inversion of IL-6 levels in relation to CRP levels to predict the
502 cytokine storm. Moreover, these observations led us to create a therapeutic
503 protocol associated with the clinical picture: This follow-up allowed the patients
504 to be subclassified into: (i) those whose antibiotic therapy was able to resolve the

505 SARS-Cov-2 infection, which was defined as YELLOW PATIENTs; (ii) those
506 whose infection presented endothelial injuries evidenced by increased fibrinogen
507 and which was solved by a higher spectrum venous antibiotic therapy and
508 cutaneous anticoagulant defined here as RED PATIENTs; and (iii) the group of
509 patients with COVID-19 of greater severity in which patients developed a bacterial
510 sepsis and viral response with the cytokine storm and which was resolved with
511 administration of a broad spectrum antibiotic therapy and pulse therapy with
512 dexamethasone and an increased dose of anticoagulant defined as PURPLE
513 PATIENTs.

514 **Funding:**

515 Rondônia State Health Department Budget.

516 **Role of the Funder/Sponsor:**

517 Neither the funder/sponsor of the study (the Rondônia State Health Department)
518 had any role in design and conduct of the study; collection, management,
519 analysis, and interpretation of the data; preparation, review, or approval of the
520 manuscript; or decision to submit the manuscript for publication. Neither the
521 funder nor the sponsor had any right to veto publication or to control the decision
522 regarding to which journal the manuscript was submitted. All drafts of the
523 manuscript were prepared by the authors.

524 **Author Contributions**

525 SPMMF, FSM and RHM conceived of the study and wrote the initial proposal.
526 SPMMF, FSM, RHM, SAB, LMAC contributed intellectually to the protocol
527 development. PAN estimated the sample size and performed all statistical
528 analysis. SPMMF, FSM, RHM, ABS and DCOM were the lead for the logistics

529 and data collection for the study. FSM, ABS, DCOM, PJG, ELO, JAL, YOC and
530 RSP actively reviewed all data from patients treated by the Multidisciplinary Home
531 Medical Care Service. PJG, ELO, did the laboratory work. The initial draft of the
532 Article was written by PAN and SPMMF, who had full access to and verified all
533 the data underlying the study. All authors had access to the data, agreed to
534 submit for publication, and vouch for the integrity, accuracy, and completeness
535 of the data and for the fidelity of the patients' laboratory data. SPMMF, JPZ, RHM,
536 LMCA and PAN contributed intellectually to the manuscript. All authors approved
537 the final submitted version.

538

539 **Data sharing**

540 Anonymized participant data can be made available upon requests directed to
541 the corresponding author. Proposals will be reviewed on the basis of scientific
542 merit. After approval of a proposal, data can be shared through a secure online
543 platform after signing a data access agreement.

544

545 **Conflict of Interest Disclosures**

546 The Healthy Secretariat of Rondônia State provided the costs for Multidisciplinary
547 Home Care Service, supplies and medicines. The latter were provided by the
548 Management and Pharmaceutical Assistance Coordination (CGAF). The State
549 Laboratory of Pathologies and Clinical Analysis from Rondônia State (LEPAC)
550 provided laboratory markers for monitoring patients during subsequent daily
551 follow-up. All other authors declare no competing interests.

552

553 **Acknowledgments**

554 This study had a financial support from Healthy Secretariat of Rondônia State,
555 Brazil. Laboratory supplies, collection supplies and related materials: Fundação
556 Oswaldo Cruz (Fiocruz) - INOVA: VPPCB-005-FIO-20-2-79 and FAPEAM
557 Programa PCTI-EMERGESAÚDE Edital Nº. 006/2020 (Number
558 01.02.016301.01078/2021). **Projeto financiado com recursos do Programa de**
559 **Excelência** em Pesquisa Básica e Aplicada em Saúde do Instituto Leônidas &
560 Maria Deane – ILMD/Fiocruz Amazônia – PROEP- LABS/ILMD FIOCRUZ
561 AMAZÔNIA We are grateful to all staff, particularly personnel from
562 Multidisciplinary Home Care Service who helped to monitoring and treating of
563 patients. Finally, we thank all of the participants, without whom this research
564 would not have been possible.

565

566 **Legends**

567

568 **Figure 1. Kinetics of inflammatory markers in YELLOW PATIENTs.** The
569 behavior of the markers in patients whose antibiotic therapy with amoxicillin
570 clavulanate was provided for 7 days. A) CRP levels during 16 days of follow up;
571 B) IL-6; C) Fibrinogen; D) The D-dimer; E) The ferritin curve in women; F) The
572 ferritin levels in men. Blue thin arrows indicate the beginning of antibiotic therapy.
573 The line represents the mean of data and gray area the standard deviation.

574

575 **Figure 2. Kinetics of inflammatory markers in RED PATIENTs.** The behavior
576 of the markers in patients treated with venous antibiotic and anticoagulant. A)
577 CRP levels during 16 days of follow up; B) IL-6; C) Fibrinogen; D) The D-dimer;
578 E) The ferritin curve in women; F) The ferritin levels in men. Blue thin arrows
579 indicate the beginning of antibiotic therapy. Red thin arrows indicate the
580 beginning of anticoagulant therapy. The line represents the mean of data and
581 gray area the standard deviation.

582

583 **Figure 3. Kinetics of inflammatory markers in PURPLE PATIENTs.** The
584 behavior of the markers in patients treated with venous antibiotic and
585 anticoagulant. A) CRP levels during 16 days of follow up; B) IL-6; C) Fibrinogen;
586 D) The D-dimer; E) The ferritin curve in women; F) The ferritin levels in men. Blue
587 thin arrows indicate the beginning of antibiotic therapy. Red thin arrows indicate
588 the beginning of anticoagulant therapy. Blue thick arrow indicates broad-
589 spectrum antibiotic therapy in order to prevent superinfections; Red thick arrow
590 indicates the increase in anticoagulation therapy with enoxaparin of 2 mg/kg day;
591 Green thick arrow indicates the pulse therapy due the inversion of IL-6 levels in
592 relation to CRP for the prediction of the cytokine storm. The line represents the
593 mean of data and gray area the standard deviation.

594

595 **Figure 4. Comparison of the kinetics of CRP and IL-6 in PURPLE and RED**
596 **PATIENT groups.** CRP and IL-6 kinetics allow distinguish the timing of the
597 cytokine storm in PURPLE PATIENTs. Although the units of CRP and IL-6 are
598 different, at the beginning of the disease in these two groups of patients are

599 similar, though with the peak of CRP in mg/L being higher than the peak IL-6 in
600 pg/mL. The thick lines represent the mean of data and dashed lines the standard
601 deviation, RED the IL-6 kinetics and BLUE CRP kinetics. A) PURPLE PATIENTs;
602 B) RED PATIENTs.

603

604 **Figure 5. The determination of therapy based on the dynamic of laboratory**
605 **markers.** A) YELLOW PATIENTs had their infection resolved only with
606 antibiotics. These patients showed CRP alterations of between 5.0 and 20.0 and
607 IL-6 up to 30 pg/mL and received antibiotic therapy (ABT) of 875 mg amoxicillin
608 and 125 mg potassium clavulanate every 12 h for 7 days. The other markers were
609 unaltered, and the infection was resolved in these patients. B) RED PATIENTS
610 showed increases in CRP levels to over 20 and IL-6 up to 30 pg/mL and
611 concomitant increases in fibrinogen to over 437. For the treatment of
612 opportunistic, ABT was replaced by 1 g of cefepime via venous route and 500mg
613 clarithromycin via oral route every 12 h, and patients received enoxaparin at 1
614 mg/kg/day subcutaneously for 7 days. C) PURPLE PATIENTs showed CRP
615 levels to over 20 and IL-6 up to 30 pg/mL and concomitant increases in fibrinogen
616 to over 437. For the treatment of opportunistic infections, ABT was replaced by 1
617 g of cefepime via venous route and 500mg clarithromycin via oral route every 12
618 h, and patients received enoxaparin at 1 mg/kg/day subcutaneously for 7 days.
619 CRP and IL-6 kinetics distinguished the timing of the cytokine storm with the peak
620 IL-6 in pg/mL being higher than with the peak of CRP in mg/L. The pulse therapy
621 was given with dexamethasone 20 mg on Day 1, followed by 3 days at 10 mg/day
622 and 3 days of 5 mg/day. They received an increase in the range of coverage of
623 antibiotics, with the addition of meropenem and amikacin, or tazobactam. The

624 dose of enoxaparin was increased to 2 mg/kg/day since fibrinogen rose again
625 after a few days even after 1 mg/kg/day of enoxaparin for more than 48 hours.
626 The line represents the mean of data.

627

628

629 **References**

- 630 1. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. *J Med Virol*.
631 2021;93: 250–256. doi:10.1002/jmv.26232
- 632 2. Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-
633 19. *Am J Pathol*. 2021;191: 4–17. doi:10.1016/j.ajpath.2020.08.009
- 634 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Yi Hu LZ, et al. Clinical features
635 of patients infected with 2019 novel coronavirus in Wuhan, China. *J*
636 *Formos Med Assoc*. 2020; 19–21.
- 637 4. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics
638 of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382: 1708–
639 1720. doi:10.1056/nejmoa2002032
- 640 5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T,
641 Davidson KW, et al. Presenting Characteristics, Comorbidities, and
642 Outcomes among 5700 Patients Hospitalized with COVID-19 in the New
643 York City Area. *JAMA - J Am Med Assoc*. 2020;323: 2052–2059.
644 doi:10.1001/jama.2020.6775
- 645 6. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A
646 pneumonia outbreak associated with a new coronavirus of probable bat

- 647 origin. *Nature*. 2020;579: 270–273. doi:10.1038/s41586-020-2012-7
- 648 7. Fouladseresht H, Doroudchi M, Rokhtabnak N, Abdolrahimzadehfard H,
649 Roudgari A, Sabetian G, et al. Predictive monitoring and therapeutic
650 immune biomarkers in the management of clinical complications of
651 COVID-19. *Cytokine Growth Factor Rev*. 2020.
652 doi:10.1016/j.cytogfr.2020.10.002
- 653 8. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S,
654 Wang B, et al. An inflammatory cytokine signature predicts COVID-19
655 severity and survival. *Nat Med*. 2020;26: 1636–1643.
656 doi:10.1038/s41591-020-1051-9
- 657 9. Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview:
658 Systemic Inflammatory Response Derived From Lung Injury Caused by
659 SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. *Front*
660 *Immunol*. 2020;11. doi:10.3389/fimmu.2020.01626
- 661 10. Fajgenbaum DC, June CH. Cytokine Storm. *N Engl J Med*. 2020;383:
662 2255–2273. doi:10.1056/nejmra2026131
- 663 11. McGonagle D, Ramanan A V., Bridgwood C. Immune cartography of
664 macrophage activation syndrome in the COVID-19 era. *Nat Rev*
665 *Rheumatol*. 2021. doi:10.1038/s41584-020-00571-1
- 666 12. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19,
667 SARS and MERS: are they closely related? *Clin Microbiol Infect*. 2020;26:
668 729–734. doi:10.1016/j.cmi.2020.03.026 1198-743X
- 669 13. Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q,

- 670 et al. SARS-CoV-2 infection–Associated hemophagocytic
671 lymphohistiocytosis an autopsy series with clinical and laboratory
672 correlation. *Am J Clin Pathol.* 2020;154: 466–474.
673 doi:10.1093/AJCP/AQAA124
- 674 14. Opoka-Winiarska V, Grywalska E, Roliński J. Could hemophagocytic
675 lymphohistiocytosis be the core issue of severe COVID-19 cases? *BMC*
676 *Med.* 2020;18: 1–11. doi:10.1186/s12916-020-01682-y
- 677 15. Dimopoulos G, Mast Q De, Markou N, Lachana A, Veerdonk FL Van De,
678 Dimopoulos G, et al. Favorable Anakinra Responses in Severe Covid-19
679 Patients with Secondary Hemophagocytic Lymphohistiocytosis. *Cell Host*
680 *Microbe.* 2020;28: 117-123.e1. Available:
681 <https://doi.org/10.1016/j.chom.2020.05.007>
- 682 16. Prieto-Pérez L, Fortes J, Soto C, Vidal-González Á, Alonso-Riaño M,
683 Lafarga M, et al. Histiocytic hyperplasia with hemophagocytosis and acute
684 alveolar damage in COVID-19 infection. *Mod Pathol.* 2020;33: 2139–
685 2146. doi:10.1038/s41379-020-0613-1
- 686 17. Tholin B, Hauge MT, Aukrust P, Fehrle L, Tvedt TH. Hemophagocytic
687 lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a
688 case report. *J Med Case Rep.* 2020;14: 1–5. doi:10.1186/s13256-020-
689 02503-9
- 690 18. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’
691 perspective on coronavirus disease 19 (COVID-19) and potential
692 therapeutic targets. *Clin Rheumatol.* 2020;39: 2055–2062.
693 doi:10.1007/s10067-020-05073-9

- 694 19. Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al.
695 HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis.
696 Med Pediatr Oncol. 1997;28: 342–347. doi:10.1002/(SICI)1096-
697 911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H
- 698 20. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA,
699 Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383: 1503–
700 1516. doi:10.1016/S0140-6736(13)61048-X
- 701 21. Lehmborg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G.
702 Differentiating macrophage activation syndrome in systemic juvenile
703 idiopathic arthritis from other forms of hemophagocytic
704 lymphohistiocytosis. J Pediatr. 2013;162: 1245–1251.
705 doi:10.1016/j.jpeds.2012.11.081
- 706 22. Moore C, Ormseth M, Fuchs H. Causes and significance of markedly
707 elevated serum ferritin levels in an academic medical center. J Clin
708 Rheumatol. 2013;19: 324–328. doi:10.1097/RHU.0b013e31829ce01f
- 709 23. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine
710 Storm’ in COVID-19. J Infect. 2020;80: 607–613.
- 711 24. Auyeung TW, Lee JSW, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use
712 of corticosteroid as treatment in SARS was associated with adverse
713 outcomes: A retrospective cohort study. J Infect. 2005;51: 98–102.
714 doi:10.1016/j.jinf.2004.09.008
- 715 25. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, et al. High-Dose
716 Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute
717 Respiratory Syndrome. Am J Respir Crit Care Med. 2003;168: 1449–

- 718 1456. doi:10.1164/rccm.200306-766OC
- 719 26. Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia
720 and Its Association with Mortality in Patients with COVID-19.pdf. J
721 Thromb Haemost. 2020. doi:10.1111/jth.14848.
- 722 27. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19
723 patients. Ann Hematol. 2020. doi:10.1007/s00277-020-04019-0
- 724 28. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy
725 and Antiphospholipid Antibodies in Patients with Covid-19. 2020;38: 22–
726 24.
- 727 29. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic,
728 biochemical and immune biomarker abnormalities associated with severe
729 illness and mortality in coronavirus disease 2019 (COVID-19): a meta-
730 analysis. Clin Chem Lab Med. 2020. doi:10.1515/cclm-2020-0369
- 731 30. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is
732 associated with decreased mortality in severe coronavirus disease 2019
733 patients with coagulopathy. J Thromb Haemost. 2020.
734 doi:10.1111/jth.14817
- 735 31. Ranucci M, Ballotta A, Dedda U Di, Bayshnikova E, Poli MD, Resta M, et
736 al. The procoagulant pattern of patients with COVID-19 acute respiratory
737 distress syndrome. J Thromb Haemost. 2020. doi:10.1111/jth.14854
- 738 32. Vinayagam S, Kamaraj Sattu. SARS-CoV-2 and coagulation disorders in
739 different organs. Life Sci J. 2020;260: 118431.
- 740 33. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus

- 741 infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from
742 the past. *J Clin Virol.* 2020;127. doi:10.1016/j.jcv.2020.104362
- 743 34. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated
744 with Acute Respiratory Distress Syndrome and Death in Patients with
745 Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern
746 Med.* 2020; 1–10. doi:10.1001/jamainternmed.2020.0994
- 747 35. Chertow DS, Memoli MJ. Bacterial coinfection in influenza: A grand
748 rounds review. *JAMA - J Am Med Assoc.* 2013;309: 275–282.
749 doi:10.1001/jama.2012.194139
- 750 36. Morens DM, Taubenberger JK, Fauci AS. Predominant Role of Bacterial
751 Pneumonia as a Cause of Death in Pandemic Influenza: Implications for
752 Pandemic Influenza Preparedness. *J Infect Dis.* 2008;198: 962–70.
753 doi:10.1086/591708.Predominant
- 754 37. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, Macfadden
755 DR, et al. Bacterial co-infection and secondary infection in patients with
756 COVID- 19: a living rapid review and meta-analysis. *Clin Microbiol Infect.*
757 2020;26: 1622–1629.
- 758 38. Van Der Meer V, Neven AK, Van Den Broek PJ, Assendelft WJJ.
759 Diagnostic value of C reactive protein in infections of the lower respiratory
760 tract: Systematic review. *Br Med J.* 2005;331: 26–29.
761 doi:10.1136/bmj.38483.478183.EB
- 762 39. Oung B, Leeson M, Crippss A. C-reactive protein: a critical review. 1991;
763 118–124.

- 764 40. Do NTT, Greer RC, Lubell Y, Dittrich S, Vandendorpe M, Nguyen VA, et
765 al. Implementation of C-reactive protein point of care testing to improve
766 antibiotic targeting in respiratory illness in Vietnamese primary care
767 (ICAT): A study protocol for a cluster randomised controlled trial. *BMJ*
768 *Open*. 2020;10: 1–9. doi:10.1136/bmjopen-2020-040977
- 769 41. Aabenhus R, Jensen JUS, Jørgensen KJ, Hróbjartsson A, Bjerrum L.
770 Biomarkers as point-of-care tests to guide prescription of antibiotics in
771 patients with acute respiratory infections in primary care. *Cochrane*
772 *Database Syst Rev*. 2014;2014. doi:10.1002/14651858.CD010130.pub2
- 773 42. Pal R, Banerjee M, Bhadada SK, Shetty AJ, Singh B, Vyas A. Vitamin D
774 supplementation and clinical outcomes in COVID-19: a systematic review
775 and meta-analysis. *J Endocrinol Invest*. 2021. doi:10.1007/s40618-021-
776 01614-4
- 777 43. Jorge-Aarón R-M, Rosa-Ester M-P. N-acetylcysteine as a potential
778 treatment for novel coronavirus disease 2019. *Futur microbiol.*. 2020; 10–
779 13. Available: <https://dx.doi.org/10.2217/fmb-2020-0074>
- 780 44. Grotto HZW. Fisiologia e metabolismo do ferro. *Rev Bras Hematol*
781 *Hemoter*. 2010;32: 8–17. doi:10.1590/S1516-84842010005000050
- 782 45. Merad M, Martin JC. Pathological inflammation in patients with COVID-
783 19: a key role for monocytes and macrophages. *Nat Rev Immunol*.
784 2020;20: 355–362. doi:10.1038/s41577-020-0331-4
- 785 46. Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-
786 19. *Am J Pathol*. 2021;191: 4–17. doi:10.1016/j.ajpath.2020.08.009

- 787 47. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med*.
788 2020;383: 2451–2460. doi:10.1056/nejmcp2009575
- 789 48. Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. *N Engl J*
790 *Med*. 2020; 1–9. doi:10.1056/nejmcp2009249
- 791 49. Robin Patel, Babady E, Theel ES, Storch GA, Pinsky BA, George K St., et
792 al. Report from the American Society for Microbiology COVID-19 COVID-
793 19. *MBio*. 2020;11: e00722-20. doi:DOI: 10.1128/mBio.00722-20
- 794 50. Seaton RA, Gibbons CL, Cooper L, Malcolm W, Mckinney R, Dundas S,
795 et al. Survey of antibiotic and antifungal prescribing in patients with
796 suspected and confirmed COVID-19 in Scottish hospitals. 2020.
- 797 51. Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE,
798 Aleva RM, et al. Recommendations for antibacterial therapy in adults with
799 COVID-19 – an evidence based guideline. *Clin Microbiol Infect*. 2021;27:
800 61–66. doi:10.1016/j.cmi.2020.09.041
- 801 52. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, Macfadden
802 DR, et al. Bacterial co-infection and secondary infection in patients with
803 COVID- 19: a living rapid review and meta-analysis. *Clin Microbiol Infect*.
804 2020;26.
- 805 53. Vinayagam S, D KSP. SARS-CoV-2 and coagulation disorders in different
806 organs. *Life Sci J*. 2020;260: 118431.
- 807 54. Muiños PJA, Otero DL, Amat-Santos IJ, País JL, Aparisi A, Antonio CEC,
808 et al. The COVID-19 lab score.pdf. *Sci Rep*. 2021;11.
- 809 55. Alunno A, Carubbi F, Rodríguez-Carrio J. Storm, typhoon, cyclone or







- 810 hurricane in patients with COVID-19? Beware of the same storm that has
811 a different origin. *RMD Open*. 2020;6: 1–4. doi:10.1136/rmdopen-2020-
812 001295
- 813 56. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et
814 al. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
815 *Arthritis and Rheumatology*. 2020. pp. 1059–1063. doi:10.1002/art.41285
- 816 57. Haigh K, Joanna Z, Irvine S, Blanchard TJ, Sajid M, Toth AG, et al.
817 Hyperinflammation with COVID-19: The key to patient deterioration? *Clin*
818 *Infect Pract*. 2020;7–8: 100033.
- 819 58. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S.
820 Cytokine storm in COVID-19: pathogenesis and overview of anti-
821 inflammatory agents used in treatment. *Clin Rheumatol*. 2020;39: 2085–
822 2094. doi:10.1007/s10067-020-05190-5
- 823 59. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
824 corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. 2020;395:
825 473–475. doi:10.1016/S0140-6736(20)30317-2
- 826 60. The_RECOVERY_Collaborative Group. Dexamethasone in Hospitalized
827 Patients with Covid-19 — Preliminary Report. *N Engl J Med*. 2020; 1–11.
828 doi:10.1056/nejmoa2021436
- 829 61. The_RECOVERY_Collaborative_Group. Colchicine in patients admitted
830 to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-
831 label, platform trial. *Lancet Respir Med*. 2021;9: 1419–1426.
832 doi:10.1016/S2213-2600(21)00435-5







- 833 62. Mcgonagle D, Sharif K, Regan AO, Bridgewood C. The Role of Cytokines
834 including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage
835 Activation Syndrome-Like Disease. *Autoimmun Rev J.* 2020;19: 102537.
- 836 63. Histiocyte Society. Recommendations and Considerations from the
837 Histiocyte Society During the Evaluation of Hospitalized COVID-19
838 Patients for Hyperinflammation. In: *Journal of Chemical Information and*
839 *Modeling [Internet].* 2020. Available:
840 [https://histiocytesociety.wildapricot.org/resources/Documents/HS COVID-](https://histiocytesociety.wildapricot.org/resources/Documents/HS_COVID-19_Statement_-_FINAL.pdf)
841 [19 Statement - FINAL.pdf](https://histiocytesociety.wildapricot.org/resources/Documents/HS_COVID-19_Statement_-_FINAL.pdf)
- 842 64. Zúñiga MÁL, Moreno-Moral A, Ocaña-Granados A, Padilla-Moreno FA,
843 Castillo-Fernández AM, Guillamón-Fernández D, et al. High-dose
844 corticosteroid pulse therapy increases the survival rate in COVID-19
845 patients at risk of hyper-inflammatory response. *PLoS One.* 2021;16: 1–
846 13. doi:10.1371/journal.pone.0243964
- 847 65. Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg
848 D, et al. Marked hyperferritinemia does not predict for HLH in the adult
849 population. *Blood.* 2015;125: 1548–1552. doi:10.1182/blood-2014-10-
850 602607
- 851 66. Colafrancesco S, Alessandri C, Conti F, Priori R. COVID-19 gone bad: A
852 new character in the spectrum of the hyperferritinemic syndrome?
853 *Autoimmun Rev.* 2020;19: 102573. doi:10.1016/j.autrev.2020.102573
854







Table 1. Biochemical and hematological parameters in the first examination



	CONTROL N=27	BLUE PATIENT N=33	YELLOW PATIENT N=28	RED PATIENT N=23	PURPLE PATIENT N=32	p
gender (% male). χ^2	44.4	48.5	32.1	43.5	71.9 *	0.0343
age	35 (24.2 ; 42.2) ^a	33 (26.5 ; 44.5) ^a	40 (33.0 ; 48.5) ^{ab}	44.5 (35.2 ; 54) ^{ab}	46 (39.7 ; 62) ^b	0.0002
Hematocrit	38 (36.18 ; 40.15)	39.35 (38.75 ; 41.58)	38.8 (37.05 ; 41.9)	37.8 (35.9 ; 40.35)	43.6 (37.35 ; 46)	0.0562
Hemoglobin	13.5 (12.28 ; 14.2)	13.8 (12.93 ; 14.8)	13.75 (12.7 ; 15)	13.2 (12.05 ; 13.88)	15.1 (12.6 ; 16.4)	0.0952
Red Blood cells	4.4 (4.245 ; 4.988)	4.71 (4.46 ; 5.04)	4.925 (4.485 ; 115.7)	4.66 (4.433 ; 304.3)	5.1 (4.55 ; 5.325)	0.0936
VCM	84.75 (83.35 ; 87.65)	85.5 (82.73 ; 87.48)	85.2 (82.35 ; 87.53)	85.1 (82.88 ; 88.23)	87.3 (83.8 ; 88.5)	0.7592
HCM	29.95 (28.65 ; 30.9)	29.45 (28.28 ; 30.83)	29.65 (28.95 ; 30.35)	29.45 (27.68 ; 30.3)	30.4 (28 ; 31.7)	0.7404
CHCM	35.05 (34.3 ; 35.53)	34.9 (33.35 ; 35.53)	34.45 (33.95 ; 34.93)	34.35 (33.7 ; 35.28)	34.3 (32.95 ; 35.65)	0.4266
Leukocytes	7400 (6675 ; 9060)	6635 (5253 ; 9833)	6035 (3340 ; 7853)	6485 (5060 ; 9638)	7870 (5850 ; 9670)	0.1909
Eosinophils	147.4 (81.7 ; 381.2)	133.9 (63.95 ; 212.9)	83.3 (0 ; 242.2)	57.7 (0 ; 136.1)	138.0 (80 ; 270.6)	0.0670
Neutrophils	4056 (2698 ; 4829)	3396 (1778 ; 5002)	2816 (1490 ; 4486)	3893 (3083 ; 6118)	5180 (3293 ; 6705)	0.1064
Lymphocytes	2172 (1492 ; 2755)	2315 (1216 ; 2906)	2045 (1650 ; 2689)	1928 (1518 ; 2640)	1754 (1224 ; 2640)	0.8516
Monocytes	427 (311.6 ; 621.3)	426.7 (197.7 ; 627.1)	407.4 (271 ; 642.2)	554.4 (320 ; 624.8)	483 (205.7 ; 646.4)	0.9063
Platelets	243500 (173750 ; 333250)	252000 (209500 ; 315250)	226500 (186250 ; 273250)	252500 (181750 ; 290000)	219000 (166500 ; 294000)	0.4995
Neu/Lymp ratio	1.902 (1.404 ; 3.007) ^{ab}	1.53 (1.225 ; 3.074) ^{ab}	1.27 (0.8698 ; 1.922) ^a	1.813 (1.444 ; 3.295) ^{ab}	2.957 (1.339 ; 3.652) ^b	0.0153
Lymp/Mono ratio	4.5 (3.216 ; 5.544)	5 (3.833 ; 6.25)	5.3 (3.771 ; 6.167)	4.4 (2.888 ; 5.065)	4.25 (2.795 ; 6.875)	0.4992
PLT/Lymp ratio	109.7 (79.41 ; 174.7)	124.2 (82.05 ; 182.7)	103.1 (93.33 ; 130.8)	125.3 (100.7 ; 153.9)	118.4 (76.33 ; 155.1)	0.8079
urea	22.4 (20.05 ; 30.25)	23.6 (20.33 ; 31.68)	22.2 (18.5 ; 26.6)	25.3 (18.1 ; 32.28)	36.4 (21.5 ; 38.9)	0.1946
creatinine	0.9 (0.6225 ; 1.045)	0.9 (0.745 ; 1.135)	0.8 (0.765 ; 1.103)	0.7 (0.6125 ; 0.925)	0.9 (0.82 ; 1.075)	0.1223
sodium	140.5 (138 ; 141.5)	137.0 (134.8 ; 141.3)	140.0 (139 ; 141)	139.5 (138 ; 141.5)	138.5 (135.5 ; 141.5)	0.2044
potassium	3.9 (3.668 ; 4.173)	3.8 (3.798 ; 4.423)	3.9 (3.645 ; 4.255)	4.0 (3.94 ; 4.38)	4.0 (3.833 ; 4.453)	0.7590
TGO	19.5 (15.75 ; 26.25)	22.0 (19 ; 30)	30.0 (19.45 ; 60.5)	31.0 (19 ; 60.25)	22.0 (18 ; 29)	0.0464
TGP	17.5 (12 ; 28.5) ^a	26.0 (15 ; 48) ^{ab}	32.3 (19 ; 67.25) ^{ab}	36.5 (21 ; 74) ^b	29.0 (22 ; 40.5) ^{ab}	0.0445


Median (25 ; 75 interquartiles). Anova Kruskal Wallis and Dunn's multiple comparisons test




A**B****C****D****E****F**








oral ATB



- Venous ATB
- 1mg/kg/ day of enoxaparin



- Increased ATB spectrum
- 1mg/kg/ day of enoxaparin

- Increase of ATB spectrum
- 2mg/kg/ day of enoxaparin
- Pulse therapy

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.21.22270828>; this version posted March 23, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).